Medincell S.A. | Mid-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Sep 2018

Income Metrics

EPS (Diluted) €0.00

Balance Sheet Metrics

Total Assets 90.5M
Total Liabilities 106.8M
Shareholders Equity -16.4M

Cash Flow Metrics

Revenue & Profitability Trend

Medincell S.A Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i25.5M9.2M9.9M4.1M8.2M
Cost of Goods Sold i00000
Gross Profit i25.5M9.2M9.9M4.1M8.2M
Gross Margin % i100.0%100.0%100.0%100.0%100.0%
Operating Expenses
Research & Development i24.3M21.1M27.9M23.6M19.5M
Selling, General & Administrative i529.0K557.0K629.0K--
Other Operating Expenses i3.8M3.7M2.7M2.8M2.5M
Total Operating Expenses i28.7M25.3M31.3M26.4M22.0M
Operating Income i-10.8M-21.0M-24.0M-23.8M-15.6M
Operating Margin % i-42.4%-229.0%-241.8%-582.3%-190.3%
Non-Operating Items
Interest Income i09.0K1.0K023.0K
Interest Expense i5.1M4.6M3.9M1.8M2.3M
Other Non-Operating Income-----
Pre-tax Income i-18.3M-25.0M-32.0M-24.8M-19.0M
Income Tax i160.0K88.0K000
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-18.4M-25.0M-32.0M-24.8M-19.0M
Net Margin % i-72.2%-273.3%-321.9%-606.5%-231.9%
Key Metrics
EBITDA i-11.2M-18.6M-26.4M-21.4M-15.7M
EPS (Basic) i-€-0.86€-1.27€-1.00€-0.86
EPS (Diluted) i-€-0.86€-1.27€-1.00€-0.86
Basic Shares Outstanding i-29071067251884992486540322044349
Diluted Shares Outstanding i-29071067251884992486540322044349

Income Statement Trend

Medincell S.A Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i59.0M19.5M6.5M24.6M47.1M
Short-term Investments i12.9M-3.0K2.0M2.8M
Accounts Receivable i1.4M2.3M2.1M799.0K883.0K
Inventory i--000
Other Current Assets100.0K-55.0K22.0K16.0K
Total Current Assets i80.6M27.3M19.6M34.1M56.3M
Non-Current Assets
Property, Plant & Equipment i7.8M4.4M4.4M6.9M4.0M
Goodwill i2.6M2.5M1.9M1.7M1.5M
Intangible Assets i2.6M2.5M1.9M1.7M1.5M
Long-term Investments-----
Other Non-Current Assets31.0K13.0K26.0K42.0K3.0K
Total Non-Current Assets i9.8M9.7M9.8M10.2M7.3M
Total Assets i90.5M36.9M29.3M44.3M63.6M
Liabilities
Current Liabilities
Accounts Payable i4.0M1.8M4.2M3.0M3.0M
Short-term Debt i7.3M6.2M40.4M28.3M3.6M
Current Portion of Long-term Debt-----
Other Current Liabilities134.0K129.0K126.0K107.0K165.0K
Total Current Liabilities i29.9M16.5M57.0M38.2M13.6M
Non-Current Liabilities
Long-term Debt i51.5M52.8M14.3M19.1M39.8M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities13.7M494.0K2.0K2.0K4.0K
Total Non-Current Liabilities i76.9M61.3M14.6M19.4M40.9M
Total Liabilities i106.8M77.8M71.6M57.7M54.5M
Equity
Common Stock i331.0K291.0K253.0K251.0K247.0K
Retained Earnings i-18.4M-25.0M-32.0M-24.8M-19.0M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i-16.4M-40.8M-42.3M-13.4M9.1M
Key Metrics
Total Debt i58.8M59.0M54.7M47.5M43.3M
Working Capital i50.7M10.8M-37.5M-4.2M42.7M

Balance Sheet Composition

Medincell S.A Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i-18.4M-25.0M-32.0M-24.8M-19.0M
Depreciation & Amortization i-----
Stock-Based Compensation i3.0M2.8M2.3M2.4M1.6M
Working Capital Changes i22.4M5.5M-4.2M-2.4M804.0K
Operating Cash Flow i14.1M-12.6M-24.9M-23.0M-13.4M
Investing Activities
Capital Expenditures i-747.0K-323.0K-528.0K-1.6M-645.0K
Acquisitions i-----
Investment Purchases i-----
Investment Sales i-----
Investing Cash Flow i-747.0K-323.0K-528.0K-1.6M-645.0K
Financing Activities
Share Repurchases i--25.0K--192.0K-
Dividends Paid i-----
Debt Issuance i013.8M30.0M3.3M18.7M
Debt Repayment i-4.1M-8.8M-24.1M-2.3M-9.3M
Financing Cash Flow i35.7M28.4M6.6M857.0K51.7M
Free Cash Flow i17.8M-13.1M-22.0M-23.3M-13.0M
Net Change in Cash i49.1M15.4M-18.8M-23.7M37.7M

Cash Flow Trend

Medincell S.A Key Financial Ratios

Valuation Ratios

Forward P/E 88.40
Price to Sales 21.09
PEG Ratio 88.40

Profitability Ratios

Profit Margin -66.50%
Operating Margin -17.30%
Return on Equity 112.65%
Return on Assets -10.56%

Financial Health

Current Ratio 2.70
Debt to Equity -4.11
Beta 1.08

Per Share Data

EPS (TTM) €-0.62
Book Value per Share €-0.50
Revenue per Share €0.94

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
medcl584.8M--112.65%-66.50%-4.11
Abivax SA 5.0B-23.91-639.37-196.12%0.00%-16.16
Valneva SE 857.1M70.644.50-38.02%-34.15%105.63
Inventiva S.A 536.1M-1.25-1.40172.73%0.00%-1.70
BNP Paribas Easy 463.1M15.99--96.39%-27.22%2.22
Nanobiotix 360.4M-5.10-103.70%0.00%-0.77

Financial data is updated regularly. All figures are in the company's reporting currency.